Jul. 7 at 8:12 PM
$ABCL
$ABCL
is holding up surprisingly well after that big move. The stock ran hard, and instead of completely giving it back, it’s been consolidating around this area. That’s usually what I want to see after a sharp move. Not straight up every day, not some crazy squeeze that dies in two sessions, but digestion. Let the stock build a new base and let people decide if this is just a short-term trade or the beginning of a bigger re-rating.
And on the company side, they keep quietly adding serious people around the business. AbCellera appointed Dr. Lynn Seely to the Board of Directors as an independent director. She has experience developing medicines across endocrinology, oncology, and women’s health, which is interesting because it also comes at a time when ABCL635 results are should be coming soon.
I’m not saying the board appointment means anything specific for ABCL635. But the timing is interesting…
